Predicting response and survival in chemotherapy-treated triple-negative breast cancerAleix Prat, Emilio Alba, Aňa Lluch et al.|British Journal of Cancer|2014Cited by 113
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, Nancy U. Lin et al.|Cancer Research|2021Cited by 88
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patientsÁngela Santonja, Emilio Alba, Nuria Ribelles et al.|Cancer Research|2016Cited by 1